October 27, 2015 FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma MILWAUKEE, WISCONSIN – This week marks another advance in the fight…
Abstract Oncolytic engineered herpes simplex viruses (HSVs) possess many biologic and functional attributes that support their use in clinical trials in children with solid tumors.…
Abstract Progress for improving outcomes in pediatric patients with solid tumors remains slow. In addition, currently available therapies are fraught with numerous side effects, often…
Dr. Cripe hosts the Columbus Blue Jackets hockey team inspirational visit to children with cancer at Nationwide Children’s Hospital, 23 October 2015. Video at https://amp.twimg.com/v/30a3ad41-3360-4aef-8628-71da8bcdeb72
An Introduction to the Science of Cancer educational video of pediatric cancers, by Timothy P. Cripe, MD, PhD, Open Therapeutics’ Viral Oncolytics Advisor and Chief of…
On 27 October 2015, the US Food and Drug Administration (FDA) approved Amgen®’s genetically engineered virus called talimogene laherparepvec (T-VEC), brand named IMLYGIC™, to treat…
